Paper40147876
Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.
Luo B and 7 others. Technol Cancer Res Treat, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study. Papers, record 40147876. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40147876
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Cytarabine | |
| Female | |
| Male | |
| Aged | |
| Granulocyte Colony-Stimulating Factor | |
| Doxorubicin | |
| Aged, 80 and over | |
| Polyethylene Glycols | |
| Middle Aged | |
| Prospective Studies | |
| Treatment Outcome |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 2 | 30892988 | Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30892988 | PubMed |
| 3 | 26139300 | Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. | J Geriatr Oncol | 2015 | https://conductscience.org/library/papers/26139300 | PubMed |
| 4 | 33604298 | Maintenance Therapy in AML. | Front Oncol | 2020 | https://conductscience.org/library/papers/33604298 | PubMed |
| 5 | 2243506 | Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. | Leukemia | 1990 | https://conductscience.org/library/papers/2243506 | PubMed |
| 6 | 11520775 | Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. | Blood | 2001 | https://conductscience.org/library/papers/11520775 | PubMed |
| 7 | 31101526 | Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. | Blood Rev | 2019 | https://conductscience.org/library/papers/31101526 | PubMed |
| 8 | 29339097 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29339097 | PubMed |
| 9 | 21828126 | A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. | Blood | 2011 | https://conductscience.org/library/papers/21828126 | PubMed |
| 10 | 35917453 | Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. | Blood | 2022 | https://conductscience.org/library/papers/35917453 | PubMed |
| 11 | 22082134 | A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. | J Hematol Oncol | 2011 | https://conductscience.org/library/papers/22082134 | PubMed |
| 12 | 38539418 | Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38539418 | PubMed |
| 13 | 30024784 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30024784 | PubMed |
| 14 | 15994282 | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. | Blood | 2005 | https://conductscience.org/library/papers/15994282 | PubMed |
| 15 | 25987659 | International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. | Blood | 2015 | https://conductscience.org/library/papers/25987659 | PubMed |
| 16 | 20668231 | Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. | Blood | 2010 | https://conductscience.org/library/papers/20668231 | PubMed |
| 17 | 37363050 | A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML. | Leuk Res Rep | 2023 | https://conductscience.org/library/papers/37363050 | PubMed |
| 18 | 30630862 | Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. | Blood | 2019 | https://conductscience.org/library/papers/30630862 | PubMed |
| 19 | 29017371 | Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. | Expert Opin Pharmacother | 2017 | https://conductscience.org/library/papers/29017371 | PubMed |
| 20 | 14673054 | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/14673054 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CSF3 | 1440 | PubTator's text mining | https://conductscience.org/library/genes/1440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40147876
GET https://conductscience.org/api/papers/v1/40147876/references?page=2